

Curriculum vitae: Guy Brusselle (MD, PhD):

Summary :

Guy Brusselle received his medical degree (M.D.) at Ghent University in 1990. Investigating the functional role of cytokines interleukin-4 (IL-4) and interleukin-5 (IL-5) in allergic asthma, he obtained his Ph.D. in 1997. As a respiratory physician with a keen clinical and scientific interest in asthma, severe asthma and COPD, he joined the Ghent University Hospital in 2002. Since 2008, he is professor of medicine at Ghent University, teaching “Study design” and “Immunopathology of airway diseases” to medical and biomedical students, respectively. Since 2015, he teaches the course “Methods and design of clinical studies” to master students in pharmaceutical sciences. Currently, he is head of the Laboratory for Translational Research of Obstructive Pulmonary Diseases at Ghent University. From September 2012 to October 2015, he has served the European Respiratory Society (ERS) as Guidelines Director. Since September 2016, he is the chair of the ERS Science Council.

A) Personal data:

Birthday: 14/09/1965

Private Address: Begonialaan 28, 9840 De Pinte, BELGIUM

Professional Address: Ghent University Hospital

Department of Respiratory Medicine

De Pintelaan 185

9000 Gent, BELGIUM

Tel: (32)09/332 26 04

Fax: (32)09/332 23 41

E-mail: guy.brusselle@UGent.be

B) Studies and Training:

10/1983 – 7/1990: Medicine at the University of Ghent

7/90: Medical Doctor (MD)

10/1990 – 9/1997: Specialist in training in Internal Medicine and in Respiratory Diseases;

8/97: PhD Thesis (Promotor Prof Dr R. Pauwels) : “Investigation into the functional role of cytokines in allergen-induced airway changes.” (PhD)

8/2013: training in Good Clinical Practice (GCP)

22/08/2014: certificate of training in Good Clinical Practice (GCP)

C) Professional activities:

10/1997 – 9/2002: Pulmonary Physician at Algemeen Ziekenhuis Sint-Lucas Gent

10/2002 – present: Pulmonary Physician at Ghent University Hospital;

01/2005 – present: Head of the Laboratory for Translational Research of Obstructive Pulmonary Diseases, Ghent University;

10/2002 – 09/2008: Associate Professor of Medicine (Respiratory Diseases as well as Design of Clinical Research) at Faculty of Medicine, Ghent University;

10/2008 – present: Professor of Medicine at Faculty of Medicine, Ghent University;

01/2007–present: Expert at the Fund for Occupational Diseases, Medical Commission for Respiratory Diseases (Belgium);
01/2010–12/2016: Expert at the Scientific Commission Med6 of the Fund for Scientific Research (Belgium; Flanders).
06/2013-present: Professor at the Departments of Respiratory Medicine and Epidemiology at Erasmus Medical Center Rotterdam, the Netherlands.

D) Leadership within the European Respiratory Society (ERS):

10/2008-09/2011: Secretary of ERS Group on Airway Pharmacology and Treatment (Group 5.1)
10/2011-09/2012: Chair of ERS Group on Airway Pharmacology and Treatment (Group 5.1)
04/2012- 09/2015: Guidelines Director of European Respiratory Society (ERS)
09/2014: Fellow of the European Respiratory Society (FERS).
09/2016- present: ERS Science Council Chair elect.

E) Interests:

1 / pathogenesis of asthma, including severe asthma
2 / pathogenesis of COPD, including preclinical and translational research (murine models of COPD; human clinical studies and epidemiologic studies; immunology and genetics)
3 / clinical trials (mostly phase II and III) in asthma, severe asthma and COPD (both pharma-sponsored and investigator-initiated interventional studies)
4/ observational studies of asthma and COPD (including cohort studies encompassing clinical epidemiology, genetic epidemiology and pharmaco-epidemiology).

F) Membership:

1/ European Respiratory Society (ERS): current ERS Science Council Chair
2/ American Thoracic Society (ATS): member of the Documents Development and Implementation Committee
3/ Belgian Society of Pneumology (BVP): scientific secretary
4/ Respiratory Effectiveness Group (REG): founding member.

G) Prizes:

1993 and 94: Allen Lecturer's Award, granted by the Belgian Society of Pneumology
1996: Boehringer-Ingelheim price for Pneumology, granted by the Belgian Society of Pneumology (12.500 Euro)
2007: Astra Zeneca Foundation Asthma & COPD Award, granted by the Belgian Fund for Scientific Research (25.000 Euro)
2010: ERS COPD Research Award, granted by the European Respiratory Society (ERS) (50.000 Euro).
2015: Price Dr. Schamelhout-Koettlitz, awarded by the Belgian Royal Academy of Medicine.
2016: Prometheus price for Scientific Research, awarded by Ghent University.

G) Grants: received numerous national grants (via FWO and IWT); participates in several European research networks (e.g. CADSET; BIOAIR; GA2LEN; EU 7th framework; HORIZON 2020; LIFECYCLE)

H) Publications: more than 240 papers in international peer-reviewed medical journals (A1).

I) Promotor: Supervised defended PhD theses:

- 1) Ken Bracke (27/06/2007): Role of proteases and chemokine receptors in a murine model of COPD.
- 2) Ingel Demedts (2007): Role of dendritic cells and matrix metalloproteinase-12 in the pathogenesis of COPD.
- 3) Yannick van Durme (25/06/2010): New insights into the epidemiology of and risk factors for COPD.
- 4) Tine Demoor (09/06/2010): Cigarette smoke-induced lymphoid neogenesis and inflammation in a murine model of chronic obstructive pulmonary disease (COPD).
- 5) Nele Pauwels (04/07/2011): The functional role of the innate immune system in the pathogenesis of COPD.
- 6) Geert Van Pottelberge (19/12/2011): The role of dendritic cells, pentraxin-3 and microRNAs in the pathogenesis of COPD.
- 7) Stephanie Verschuere (16/04/2012): The effect of cigarette smoke on the mucosal immune system of the small intestine.
- 8) Daan Loth (30/10/2013): at Erasmus MC Rotterdam: Epidemiology of lung function and COPD.
- 9) Pauline Boeckxstaens (29/09/2014): Multimorbidity: A quantitative and qualitative exploration in primary care.
- 10) Lisa Dupont (24/11/2014): Role of serotonin receptor 5-HT₄ and soluble guanylyl cyclase in the pathogenesis of COPD.
- 11) Lies Lahousse (11/11/2014): Epidemiology of comorbidities in COPD.
- 12) Fien Verhamme (11/05/2015): Role of lymphoid follicles and TGF-beta superfamily in the pathogenesis of COPD.
- 13) Eline Tommelein (2016): The evolving role of the community pharmacist.
- 14) Leen Seys (01/12/2016): Mucosal immunity in COPD: from mucociliary dysfunction to lymphoid follicles.

J) International collaboration:

International collaboration with numerous individual academic centres as well as within European networks.

1) Academic centres:

Erasmus Medical Center Rotterdam (B. Stricker, A. Hofman);
University Medical Center Leiden (P. Hiemstra, C. Taube);
University Medical Center Groningen (D. Postma, W. Timens, M. Boezen);
University Medical Center Maastricht (E. Wouters, A. Schols);
Kennedy Institute, Oxford University (P. Venables);

Oxford University (I. Pavord, M. Bafadel)

Heidelberg University (M. Mall);

U4 Collaboration on the Ageing Lung: international collaboration between the Universities of Ghent, Groningen, Göttingen and Uppsala.

2) European networks:

BIOAIR, GA2LEN, U-BIOPRED, ERS Clinical Research Collaborations (CRCs) such as EMBARC (Bronchiectasis) and SHARP (Severe Asthma).

3) International consortia and global networks:

CHARGE; TAGC; ICGC; EAGLE; ESCAPE; LIFECYCLE; Respiratory Effectiveness Group (REG).

K) Editor:

Associate Editor of the Lancet Respiratory Medicine (since 05/2012) and the American Journal of Respiratory and Critical Care Medicine (AJRCCM) (since 01/2011).

L) Reviewer:

Regular reviewer for multiple scientific journals including:

New England Journal of Medicine (NEJM), the Lancet, the Lancet Respiratory Medicine, American Journal of Respiratory and Critical Care Medicine (AJRCCM), European Respiratory Journal (ERJ), Thorax, American Journal of Respiratory Cell and Molecular biology (AJRCMB), American Journal of Physiology, Annals of the American Thoracic Society (ATS), Chest, Clinical and Experimental Allergy (CEA), Respiratory Research, Respiratory Medicine, and Pulmonary Pharmacology and Therapeutics (PPT).

L) Coordinating investigator of the AZISAST study (AZithromycin in Severe ASThma study): an investigator-initiated, multi-center, randomised, placebo-controlled, double-blind, parallel-group study of the efficacy and safety of azithromycin as add-on therapy in adult patients with severe asthma. RCT sponsored by the Flemish authorities (IWT / TBM). Please see www.clinicaltrials.gov .